FDA has approved 26 new molecular entities this year

12/12/2013 | Medical Marketing & Media

Twenty-six new molecular entities have been approved so far in 2013 in the U.S., said Dr. Richard Moscicki, the deputy center director for science operations at the FDA's Center for Drug Evaluation and Research. Both approvals and applications are down from last year. Rare disease indications accounted for 36% of the new drug approvals, and three of the approved medications this year were cleared with the breakthrough therapy status.

View Full Article in:

Medical Marketing & Media

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA